blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2564872

EP2564872 - Mazindol alone or in combination with iron for the treatment of attention-deficit/hyperactivity disorder [Right-click to bookmark this link]
Former [2013/10]Combination of mazindol in the treatment of attention-deficit/hyperactivity disorder
[2020/04]
StatusNo opposition filed within time limit
Status updated on  16.04.2021
Database last updated on 07.10.2024
FormerThe patent has been granted
Status updated on  08.05.2020
FormerGrant of patent is intended
Status updated on  05.02.2020
FormerExamination is in progress
Status updated on  13.01.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
NLS Pharmaceutics AG
Alter Postplatz 2
6370 Stans / CH
[2020/41]
Former [2018/26]For all designated states
NLS-1 Pharma AG
Alter Postplatz 2
6370 Stans / CH
Former [2013/10]For all designated states
ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS
3, avenue Victoria
75004 Paris / FR
Inventor(s)01 / Konofal, Eric
Château de Beauval, 2 Avenue de Compiègne
60300 Senlis / FR
 [2013/10]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2013/10]
Application number, filing date12189703.711.04.2007
[2013/10]
Priority number, dateFR2006000319711.04.2006         Original published format: FR 0603197
[2013/10]
Previously filed application, dateEP2007072798011.04.2007
[2013/10]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report 
No.:EP2564872
Date:06.03.2013
Language:FR
[2013/10]
Type: B1 Patent specification 
No.:EP2564872
Date:10.06.2020
Language:FR
[2020/24]
Search report(s)(Supplementary) European search report - dispatched on:EP05.02.2013
ClassificationIPC:A61K31/4188, A61K33/26, A61P25/26
[2020/04]
CPC:
A61K31/4188 (EP,US); A61K31/41 (EP,US); A61K31/4184 (EP,US);
A61K31/555 (EP,US); A61K33/26 (EP,US); A61K45/06 (EP,US);
A61K9/0053 (US); A61P25/00 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/26 (EP);
A61P25/28 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/4184, A61K2300/00 (US,EP);
A61K31/4188, A61K2300/00 (US,EP);
A61K31/41, A61K2300/00 (EP,US);
A61K33/26, A61K2300/00 (US,EP)
Former IPC [2013/10]A61K45/06, A61K31/4188, A61K33/26, A61P25/26
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/24]
Former [2013/10]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Mazindol als Einzelwirkstoff oder in Kombination mit Eisen zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung[2020/04]
English:Mazindol alone or in combination with iron for the treatment of attention-deficit/hyperactivity disorder[2020/04]
French:Mazindol en tant que seul principe actif ou en combinaison avec du fer pour le traitement du déficit de l'attention/hyperactivité[2020/04]
Former [2013/10]Assoziation von Mazindol zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung
Former [2013/10]Combination of mazindol in the treatment of attention-deficit/hyperactivity disorder
Former [2013/10]Association du mazindol dans le traitement du déficit de l'attention/hyperactivité
Examination procedure05.09.2013Examination requested  [2013/42]
06.09.2013Amendment by applicant (claims and/or description)
16.01.2017Despatch of a communication from the examining division (Time limit: M06)
25.07.2017Reply to a communication from the examining division
17.01.2019Despatch of a communication from the examining division (Time limit: M02)
15.03.2019Reply to a communication from the examining division
19.12.2019Cancellation of oral proceeding that was planned for 23.01.2020
23.01.2020Date of oral proceedings (cancelled)
06.02.2020Communication of intention to grant the patent
29.04.2020Fee for grant paid
29.04.2020Fee for publishing/printing paid
29.04.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07727980.0  / EP2004183
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070727980) is  25.10.2010
Opposition(s)11.03.2021No opposition filed within time limit [2021/20]
Fees paidRenewal fee
06.02.2013Renewal fee patent year 03
06.02.2013Renewal fee patent year 04
06.02.2013Renewal fee patent year 05
06.02.2013Renewal fee patent year 06
06.02.2013Renewal fee patent year 07
26.03.2014Renewal fee patent year 08
09.04.2015Renewal fee patent year 09
31.03.2016Renewal fee patent year 10
28.04.2017Renewal fee patent year 11
30.04.2018Renewal fee patent year 12
09.04.2019Renewal fee patent year 13
30.03.2020Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.04.2007
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
MT10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
[2024/41]
Former [2023/27]HU11.04.2007
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2023/24]CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2022/23]CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2022/10]CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
PT12.10.2020
Former [2021/50]CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
MC10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/24]CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
RO10.06.2020
SI10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/20]CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
RO10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/10]CZ10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
RO10.06.2020
SK10.06.2020
BG10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/09]CZ10.06.2020
EE10.06.2020
FI10.06.2020
LT10.06.2020
LV10.06.2020
RO10.06.2020
BG10.09.2020
GR11.09.2020
PT12.10.2020
Former [2021/01]FI10.06.2020
LT10.06.2020
LV10.06.2020
BG10.09.2020
GR11.09.2020
Former [2020/50]FI10.06.2020
LT10.06.2020
LV10.06.2020
GR11.09.2020
Former [2020/48]FI10.06.2020
LT10.06.2020
Former [2020/47]LT10.06.2020
Documents cited:Search[A]GB2144410  (STABIL BIOTERAPICO FARMACHIM) [A] 12,13 * the whole document *;
 [A]WO9111184  (UNIV YALE [US]) [A] 1-13 * page 2, lines 13-31; claims 9,10,16,23 *;
 [A]WO9321917  (UNIV YALE [US]) [A] 1-13 * page 2, line 27 - page 3, line 11; example 1; claims 1,2,11 *;
 [A]WO02053104  (SENTION INC [US], et al) [A] 1-13 * page 28, line 18 - page 29, line 33; figure 22; claims 4,13 *;
 [XYI]WO2004091546  (EURO CELTIQUE SA [LU], et al) [X] 1,6,13 * claims 2,21,33 * [Y] 5,9-12 [I] 2-4,7;
 [Y]WO2004105744  (ASSIST PUBL HOPITAUX DE PARIS [FR], et al) [Y] 5,9-12 * claims 1-3,9-13,15-18,21 *;
 [A]  - VAZQUEZ-ALVAREZ A ET AL, "MAZINDOL EFFECTS ON LEAD - INDUCED LOCOMOTOR HYPERACTIVITY IN MICE.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2002), Database accession no. PREV200300327254, XP002395485 [A] 1-13 * abstract *
    [ ] - SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, (2002), vol. 2002, pages Abstract No. 804.6 URL - http://sf
 [A]  - WALTHER B W, "TREATING RESTLESS LEGS SYNDROME: CURRENT PATHOPHYSIOLOGICAL CONCEPTS AND CLINICAL TRIALS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (200204), vol. 11, no. 4, ISSN 1354-3784, pages 501 - 514, XP009024933 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1517/13543784.11.4.501
 [A]  - ZHOU J, "Norepinephrine transporter inhibitors and their therapeutic potential", DRUGS OF THE FUTURE 2004 SPAIN, (2004), vol. 29, no. 12, ISSN 0377-8282, pages 1235 - 1244, XP002395478 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1358/dof.2004.029.12.855246
by applicant   - SLEEP, SLEEP, (20011215), vol. 25, no. 2, pages 213 - 8
    - GRUBER ET AL., "instability of sleep patterns in children with attention-deficit/hyperactivity disorder", J AM ACAD CHILD ADOLESC PSYCHIATRY, (2000), vol. 39, no. 4, pages 495 - 501
    - RUIVARD ET AL., REV. MéD. INTERNE, (2000), vol. 21, pages 837 - 843
    - LOZOFF, ADV PEDIATR, (1989), vol. 6, pages 331 - 59
    - MARDER F ET AL., NEUROLOGY, (1998), vol. 50, no. 4, pages 1138 - 40
    - BIEDERMAN J; SWANSON JM; WIGAL SB; KRATOCHVIL CJ; BOEFLNER SW; EARL CQ; JIANG J; GREENHILL L., "Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study", PEDIATRICS, (2005), vol. 116, page E777
    - BIEDERMAN J; HEILIGENSTEIN JH; FANES DE; GALIL N; DITTMANN R; EMSLIE GJ; KRATOCHVIL CJ; LAWS HF; SCHUH KJ, "Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder", PEDIATRICS, (2002), vol. 110, no. 6, page 75
    - BUSBY K; FIRESTONE P; PIVIK RT, "Sleep pattem in hyperkinetic and normal children", SLEEP, (1981), vol. 4, pages 366 - 83
    - CARSKADON MA; DEMENT WC, "The multiple sleep latency test: what does R measure?", SLEEP, (1982), vol. 5, pages 67 - 72
    - CARSKADON MA; DEMENT WC; MITLER MM; ROTH T; WESTBROOK PR; KEENAN S, "Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness", SLEEP, (1986), vol. 9, pages 519 - 24
    - CHERVIN RD; ARCHBOLD KH; DILLON JE; PITUCH KJ; PANAHI P; DAHI RE; GUILLEMINAULT C., "Associations between symptoms of inattention, hyperactivity, restless legs, and periodic leg movements", SLEEP, (20011215), vol. 25, no. 2, pages 213 - 8
    - CORKUM P; MOLDOFSKY H; HOGG-JOHNSON; HUMPHRIES T.; TANNOCK R, "Sleep problems in children with attention-deticit/hyperactivity disorder: impact of Subtype, comorbidity, and stimulant medication", J AM ACAD CHILD ADOLESC PSYCHIATRY, (1999), vol. 38, pages 1285 - 93
    - CORKUM P; TANNOCK R; MOLDOFSKY H, "Sleep disturbances in children with attention deficit hyperactivity disorder", J AM ACAD CHILD ADOLESC PSYCHIATRY, (1998), vol. 37, no. 6, pages 637 - 46
    - CORTESE S; KONOFAL E; LECENDREUX M; AMULF I; MOUREN MC; DARRA F; DALLA BEMARDINA B., "Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature", SLEEP, (2005), vol. 28, no. 8, pages 1007 - 13
    - GOLAN N; SHAHAR E; RAVID S; PILLAR G, "Sleep disorders and daytime sleepiness in children with attention-deficit/hyperactive disorder", SLEEP, (2004), vol. 15, pages 261 - 6
    - GREENHILL LL; PUIG-ANTICH J; GOETZ R; HANLON C, "Sleep architecture and REM sleep measure in prepubertal children with attention deficit disorder with hyperactivity", SLEEP, (1983), vol. 6, pages 91 - 101
    - HADIER AJ, "Mazindol, a new non-amphetamine anorexigenic agent", J CLIN PHARMACOL NEW DRUGS, (1972), vol. 12, pages 453 - 8
    - KAPLAN BJ; MCNICOL J; CONTE RA; MOGHADAM HK, "Sleep disturbance in preschool aged hyperactive and nonhyperactive children", PEDIATRICS, (1987), vol. 80, pages 839 - 44
    - KONOFAL E; LECENDREUX M; BOUVARD M; MOUREN-SIMÉONI M-C, "High levels of nocturnal activity in children with ADHD : a video analysis", PSYCHIATRY CLIN NEUROSCI, (2001), vol. 55, no. 2, pages 97 - 103
    - KONOFAL E; LECENDREUX M; MOUREN-SIMEONI M-C, "Sleep in children with attention deficit/hyperactivity disorder: a restatement on sleep studies", ANN MED PSYCHOL, (2002), vol. 160, pages 105 - 17
    - KONOFAL E; LECENDREUX M; ARNULF I; MOUREN MC, "Iron deficiency in children with attention-deficit/hyperactivity disorder", ARCH PEDIATR ADOLESC MED., (2004), no. 12, page 158
    - KONOLÀL E; CORTESE S; LECENDREUX M; AMULF I; MOUREN MC, "Effectiveness of Iron supplementation in a young child With Attention-Deficit/Hyperactivity Disorder", PEDIATRICS, (2005), vol. 116, no. 5
    - LECENDREUX M; KONOFAL E; BOUVARD M; FALISSARD B; MOUREN-SIMEONI M-C, "Sleep and alertness in children with ADHD", J CHILD PSYCHOL PSYCHIATRY, (2000), vol. 41, no. 6, pages 803 - 12
    - MICK E; BIEDERMAN J; JETTON J; FARAONE SV, "Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatrie comorbidity and pharmacotherapy", J CHILD ADOLESC PSYCHOPHARMACOL FALL, (2000), vol. 10, no. 3, pages 223 - 31
    - PALM L; PERSSON E; BJERRE L; ELMQVIST D, "Sleep and wakefulness in preadolescent children with deficits in attention, motor control and perception", ACTA PAEDIATR, (1992), vol. 81, pages 618 - 24
    - PICCHIETTI DL; WALTERS AS, "Restless legs syndrome and periodic Iimb movement disorder in children and adolescents: comorbidity with attention-deficit/hyperactivity disorder", CHILD ADOLESC. PSYCHIATRY CLIN N AM, (1996), vol. 5, pages 729 - 40
    - PLATON MJR; VELA BUENO A; ESPINAR SIERRA J; KALES S, "Hypnopolygraphic alterations in attention deficit disorder (ADD) children", INTERN J NEUROSCI, (1990), vol. 53, pages 87 - 101
    - POPPER CW, "Pharmacologie alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder", CHILD ADOLESC PSYCHIATR CLIN N AM, (2000), vol. 9, no. 3, pages 605 - 46
    - RUGINO TA; COPLEY TC, "Effects of modafinil in children with attention deficit/hyperactivity disorder: an open study", J AM ACAD CHILD ADOLESC PSYCHIATRY, (2001), vol. 40, no. 2, pages 230 - 5
    - SHINDLER J; SCHACHTER M; BRINCAT S; PARKES JD, "Amphetamine, mazindol, and fencamfamin in narcolepsy", BR MED J., (1985), vol. 20, pages 1167 - 70
    - TROMMER BL; HOEPPNER JB; ROSENBERG RS; ARMSTRONG KJ; ROTHSTEIN JA, "Sleep disturbance in children with attention deficit disorder", ANN NEUROLOGY, (1988), vol. 24, page 322
    - WALTERS AS; MANDELBAUM DE; LEWIN DS; KUGLER S; ENGLAND SJ; MILLER M, "Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD", PEDIATR NEUROL, (2000), vol. 22, no. 3, pages 182 - 6
    - WEINBERG WA; BRUMBACK RA, "Primary disorder of vigilance: a novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness", J PEDIATR, (1992), vol. 116, pages 720 - 5
    - WEINBERG WA; HARPER CR, "Vigilance and its disorders", NEU ROI CLIN, (1993), vol. 11, pages 59 - 78
    - WEISS M; MURRAY C; WEISS G, "Adults with attention-deficit/hyperactivity disorder: current concepts", J PSYCHIATR PRACT., (2002), vol. 28, pages 99 - 111
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.